Reta belum lulus di Malaysia, KKM pesan jangan guna ‘pen kurus’
Belum ada produk mengandungi Reta berdaftar dengan PBKD untuk digunakan di Malaysia, menurut KKM.
Retatrutide is an experimental drug currently undergoing phase three clinical trials, with no marketing approval from any global regulatory authority, according to the Pharmaceutical Control Department (KKM). Malaysian Health Minister advises the public against buying or using the supposed Retatrutide pen that claims to contain the drug, as there is no registered product with that name approved for use in Malaysia.
As of August 17, 2026, no Retatrutide-containing product has been registered with the Drug Control Authority (PBKD) for use in Malaysia, the ministry reported. The surge in online weight loss pill sales, including unprescribed injections offered to the general public without examination, prescriptions, or registered medical supervision, is concerning, the KKM added.
Using such products without proper assessment and medical supervision can lead to adverse effects and serious complications, the KKM warned. The department explained that the risk could worsen if adverse effects or complications experienced by users remain unrecognized and untreated. The Ministry's Drug Control Department has received 65 complaints and conducted 30 investigations related to weight loss products, including 17 investigations linked to online sales totaling RM477,142 for the period from January to July last year.
Between January and July 2026, 209 weight loss product advertisements, including those allegedly containing Retatrutide, were removed from e-commerce platforms. Additionally, 1,243 ads across various media channels were identified, filtered, and taken appropriate action, the KKM said. The KKM advises the public to ensure that any weight loss product they wish to purchase is registered and approved for that purpose, and obtained from a reliable source.
Product registration status can be checked through the Product Search function on the National Pharmaceutical Regulatory Agency (NPRA) website, while FarmaTag hologram authenticity can be verified using FarmaChecker in the MyUbat application. The KKM clarified that selling unregistered medication violates the 1952 Drug Sales Act (Act 368) and associated regulations, carrying penalties up to RM50,000 for the first offense and RM100,000 for subsequent offenses.
Written by urgent.news from Free Malaysia Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
